Zydus Working On New Indication For Diabetes Treatment Drug
This article was originally published in PharmAsia News
Executive Summary
Already successful in getting its NCE Lipaglyn (saroglitazar) on the India market for treating a pair of diabetes problems, Zydus Group is seeking to show the drug also can reverse the body's failure to handle fat properly.